Exploring sevoflurane consumption and CO2 emissions of individual patients undergoing noncardiac surgery using a target-controlled sevoflurane administration system
Authors' conclusion
In this large cohort of cases, this study demonstrated that controlling ET with an FGF target of 0.5 L.min-1 remained the best way to reduce sevoflurane consumption.
Study context
- Population
- Consecutive adult procedures for noncardiac surgery under GA with end-tidal (ET)-controlled sevoflurane (Aisys CS2), 12 operating rooms
- Participants
- 3,064 procedures
- Outcome
- Sevoflurane consumption (mL.min-1)
Methodological detailssingle-centre, case study, Median (IQR) duration of surgery 79 (47-124) minutes, May to September 2024
- Single-centre
- Case study
- Median (IQR) duration of surgery 79 (47-124) minutes
- May to September 2024
Main finding
As reported in the abstract
Sevoflurane consumption
Median (IQR) sevoflurane consumption, mL.min-1
0.16
0.12–0.20
Observational data: associations, not effects.
Secondary outcomes
Total sevoflurane consumption
- Total sevoflurane consumption, mL
- 19 528
Sevoflurane consumption and CO2 emission by fresh gas flow (FGF) (subgroup)
- FGF 0.8 or 1.0 L.min-1 significantly increased sevoflurane consumption and CO2 emission vs 0.5 L.min-1
- P < 0.01
Sevoflurane consumption by initial ET target (subgroup)
- Initial ET target 1.2% vs >1.2% did not change total sevoflurane consumption
Sevoflurane consumption by airway management, EI vs LM (subgroup)
- LM associated with higher consumption, specifically when duration > 120 min
- P < 0.01
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Exploring sevoflurane consumption and CO2 emissions of individual patients undergoing noncardiac surgery using a target-controlled sevoflurane administration system. J Clin Monit Comput. Published 21 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →